Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention

Marina Chavchich; Geoffrey W. Birrell; Arba L. Ager; Donna O. MacKenzie; Gavin D. Heffernan; Guy A. Schiehser; Laura R. Jacobus; G. Dennis Shanks; David P. Jacobus; Michael D. Edstein

doi:10.1128/AAC.03066-15

Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention

Marina Chavchich, Geoffrey W. Birrell, Arba L. Ager, Donna O. MacKenzie, Gavin D. Heffernan, Guy A. Schiehser, Laura R. Jacobus, G. Dennis Shanks, David P. Jacobus, Michael D. Edstein

Microbiology & Immunology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Structure-activity relationship studies of trifluoromethyl-substituted pyridine and pyrimidine analogues of 2-aminomethylphenols (JPC-2997, JPC-3186, and JPC-3210) were conducted for preclinical development for malaria treatment and/or prevention. Of these compounds, JPC-3210 [4-(tert-butyl)-2-((tert-butylamino)methyl)-6-(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)phenol] was selected as the lead compound due to superior in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, lower in vitro cytotoxicity in mammalian cell lines, longer plasma elimination half-life, and greater in vivo efficacy against murine malaria.

Original language	English (US)
Pages (from-to)	3115-3118
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	60
Issue number	5
DOIs	https://doi.org/10.1128/AAC.03066-15
State	Published - May 2016

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.03066-15

Fingerprint Dive into the research topics of 'Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention'. Together they form a unique fingerprint.

Cite this

Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention. / Chavchich, Marina; Birrell, Geoffrey W.; Ager, Arba L.; MacKenzie, Donna O.; Heffernan, Gavin D.; Schiehser, Guy A.; Jacobus, Laura R.; Shanks, G. Dennis; Jacobus, David P.; Edstein, Michael D.

In: Antimicrobial agents and chemotherapy, Vol. 60, No. 5, 05.2016, p. 3115-3118.

Research output: Contribution to journal › Article › peer-review

Chavchich, Marina ; Birrell, Geoffrey W. ; Ager, Arba L. ; MacKenzie, Donna O. ; Heffernan, Gavin D. ; Schiehser, Guy A. ; Jacobus, Laura R. ; Shanks, G. Dennis ; Jacobus, David P. ; Edstein, Michael D. / Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention. In: Antimicrobial agents and chemotherapy. 2016 ; Vol. 60, No. 5. pp. 3115-3118.

@article{1d53aa5be0d44627a3c71f1d7b044381,

title = "Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention",

abstract = "Structure-activity relationship studies of trifluoromethyl-substituted pyridine and pyrimidine analogues of 2-aminomethylphenols (JPC-2997, JPC-3186, and JPC-3210) were conducted for preclinical development for malaria treatment and/or prevention. Of these compounds, JPC-3210 [4-(tert-butyl)-2-((tert-butylamino)methyl)-6-(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)phenol] was selected as the lead compound due to superior in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, lower in vitro cytotoxicity in mammalian cell lines, longer plasma elimination half-life, and greater in vivo efficacy against murine malaria.",

author = "Marina Chavchich and Birrell, {Geoffrey W.} and Ager, {Arba L.} and MacKenzie, {Donna O.} and Heffernan, {Gavin D.} and Schiehser, {Guy A.} and Jacobus, {Laura R.} and Shanks, {G. Dennis} and Jacobus, {David P.} and Edstein, {Michael D.}",

year = "2016",

month = may,

doi = "10.1128/AAC.03066-15",

language = "English (US)",

volume = "60",

pages = "3115--3118",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention

AU - Chavchich, Marina

AU - Birrell, Geoffrey W.

AU - Ager, Arba L.

AU - MacKenzie, Donna O.

AU - Heffernan, Gavin D.

AU - Schiehser, Guy A.

AU - Jacobus, Laura R.

AU - Shanks, G. Dennis

AU - Jacobus, David P.

AU - Edstein, Michael D.

PY - 2016/5

Y1 - 2016/5

N2 - Structure-activity relationship studies of trifluoromethyl-substituted pyridine and pyrimidine analogues of 2-aminomethylphenols (JPC-2997, JPC-3186, and JPC-3210) were conducted for preclinical development for malaria treatment and/or prevention. Of these compounds, JPC-3210 [4-(tert-butyl)-2-((tert-butylamino)methyl)-6-(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)phenol] was selected as the lead compound due to superior in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, lower in vitro cytotoxicity in mammalian cell lines, longer plasma elimination half-life, and greater in vivo efficacy against murine malaria.

AB - Structure-activity relationship studies of trifluoromethyl-substituted pyridine and pyrimidine analogues of 2-aminomethylphenols (JPC-2997, JPC-3186, and JPC-3210) were conducted for preclinical development for malaria treatment and/or prevention. Of these compounds, JPC-3210 [4-(tert-butyl)-2-((tert-butylamino)methyl)-6-(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)phenol] was selected as the lead compound due to superior in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, lower in vitro cytotoxicity in mammalian cell lines, longer plasma elimination half-life, and greater in vivo efficacy against murine malaria.

UR - http://www.scopus.com/inward/record.url?scp=84964815043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964815043&partnerID=8YFLogxK

U2 - 10.1128/AAC.03066-15

DO - 10.1128/AAC.03066-15

M3 - Article

C2 - 26856849

AN - SCOPUS:84964815043

VL - 60

SP - 3115

EP - 3118

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -